Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.61 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | F11 | P03951 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979565 | 0.84 | LPL (0.57) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL9180552 | 0.82 | LMNA (0.52) | LMNA | |
| SCHEMBL6356134 | 0.79 | TRPV1 (0.58) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL6351213 | 0.79 | LPL (0.53) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL3731326 | 0.78 | LPL (0.58) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL330333 | 0.76 | LPL (0.45) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL19272703 | 0.76 | LPL (0.46) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL257735 | 0.76 | LPL (1.00) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL12961019 | 0.76 | LMNA (0.43) | LMNA | |
| SCHEMBL1039696 | 0.76 | ALDH1A1 (0.53) | CA2CA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP. | 2017-11-23 | — | — | US | disclosed |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP. | 2017-11-23 | — | — | US | disclosed |
| US-9376400-B2 | Process for the synthesis of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376400-B2 | Process for the synthesis of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA SUBSIDIARY CORP. | 2016-05-19 | — | — | US | disclosed |
| EP-2673281-B1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | MELINTA SUBSIDIARY CORP. | 2015-06-11 | — | — | US | disclosed |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | MELINTA SUBSIDIARY CORP. | 2015-06-11 | — | — | US | disclosed |
| US-8796465-B2 | Process for the syntheses of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796465-B2 | Process for the syntheses of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140031402-A1 | Process for the Syntheses of Triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031402-A1 | Process for the Syntheses of Triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8399660-B2 | Process for the synthesis of triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399660-B2 | Process for the synthesis of triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100234615-A1 | Process for the synthesis of triazoles | MELINTA SUBSIDIARY CORP. | 2010-09-16 | — | — | US | disclosed |
| US-20100234615-A1 | Process for the synthesis of triazoles | MELINTA SUBSIDIARY CORP. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234615-A1 | Process for the synthesis of triazoles | PROKR1, SI, IL33 | LPL 4214/4885LIPG 4244/4885CA2 4058/4885 |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CUTA, CYP19A1, KAT2A | LPL 1855/4885LIPG 2720/4885CA2 3115/4885 |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | CUTA, CYP17A1, HSD17B11 | LPL 1311/4885LIPG 3555/4885CA2 4125/4885 |
| US-20140031402-A1 | Process for the Syntheses of Triazoles | PROKR1, VIP, SI | LPL 3740/4885LIPG 4099/4885CA2 4057/4885 |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | PROKR1, SI, IL33 | LPL 4214/4885LIPG 4244/4885CA2 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.